{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:38:41Z","timestamp":1740137921326,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Redes Telem\u00e1ticas de Investigaci\u00f3n Cooperativa en Salud","award":["RD06\/ 0006\/0021"],"award-info":[{"award-number":["RD06\/ 0006\/0021"]}]},{"name":"Pfizer\/ViiV Healthcare","award":["WS843473"],"award-info":[{"award-number":["WS843473"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD14\/00320"],"award-info":[{"award-number":["CD14\/00320"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondo de Investigaciones Sanitarias","award":["CD014\/0025"],"award-info":[{"award-number":["CD014\/0025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12967-017-1367-5","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T13:11:30Z","timestamp":1513775490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0239-8417","authenticated-orcid":false,"given":"A.","family":"Gonzalez-Serna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ferrando-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tarancon-Diez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. S.","family":"De Pablo-Bernal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Dominguez-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. \u00c1.","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ruiz-Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"1367_CR1","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/QAD.0b013e32833a3946","volume":"24","author":"AI Sighem Van","year":"2010","unstructured":"Van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F, ATHENA national observational cohort study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24:1527\u201335.","journal-title":"AIDS"},{"key":"1367_CR2","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1093\/jac\/dku112","volume":"69","author":"A Gonzalez-Serna","year":"2014","unstructured":"Gonzalez-Serna A, Chan K, Yip B, Chau W, McGovern R, Samji H, Lima VD, Hogg RS, Harrigan R. Temporal trends in the discontinuation of first-line antiretroviral therapy. J Antimicrob Chemother. 2014;69:2202\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1367_CR3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","volume":"62","author":"SG Deeks","year":"2011","unstructured":"Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141\u201355.","journal-title":"Annu Rev Med"},{"key":"1367_CR4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40265-016-0546-7","volume":"76","author":"DC Hsu","year":"2016","unstructured":"Hsu DC, Sereti I. Serious non-AIDS events: therapeutic targets of immune activation and chronic inflammation in HIV infection. Drugs. 2016;76:533\u201349.","journal-title":"Drugs"},{"key":"1367_CR5","unstructured":"British HIV Association guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012 (updated November 2013). http:\/\/www.bhiva.org\/HIV-1-treatment-guidelines-2012.aspx . Accessed 28 Nov 2017."},{"key":"1367_CR6","unstructured":"European AIDS Clinical Society Guidelines. Clinical management and treatment of HIV-infected adults in Europe (Version 8.2, January 2017). http:\/\/www.eacsociety.org\/files\/guidelines_8.2-english.pdf . Accessed 28 Nov 2017."},{"key":"1367_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1742-6405-10-33","volume":"10","author":"AC Achhra","year":"2013","unstructured":"Achhra AC, Boyd MA. Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Res Ther. 2013;10:33.","journal-title":"AIDS Res Ther"},{"key":"1367_CR8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/infdis\/jit006","volume":"207","author":"E Leeansyah","year":"2013","unstructured":"Leeansyah E, Cameron PU, Solomon A, Tennakoon S, Velayudham P, Gouillou M, Spelman T, Hearps A, Fairley C, de Smit V, Pierce AB, Armishaw J, Crowe SM, Cooper DA, Koelsch KK, Liu JP, Chuah J, Lewin SR. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013;207:1157\u201365.","journal-title":"J Infect Dis"},{"key":"1367_CR9","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1128\/AAC.01406-12","volume":"56","author":"MC Romero-S\u00e1nchez","year":"2012","unstructured":"Romero-S\u00e1nchez MC, Machmach K, Gonzalez-Serna A, Genebat M, Pulido I, Garc\u00eda-Garc\u00eda M, Alvarez-R\u00edos AI, Ferrando-Martinez S, Ruiz-Mateos E, Leal M. Effect of maraviroc on HIV disease progression-related biomarkers. Antimicrob Agents Chemother. 2012;56:5858\u201364.","journal-title":"Antimicrob Agents Chemother"},{"key":"1367_CR10","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/infdis\/jiu180","volume":"210","author":"MM Pozo-Balado","year":"2014","unstructured":"Pozo-Balado MM, Mart\u00ednez-Bonet M, Rosado I, Ruiz-Mateos E, M\u00e9ndez-Lagares G, Rodr\u00edguez-M\u00e9ndez MM, Vidal F, Mu\u00f1oz-Fern\u00e1ndez MA, Pacheco YM, Leal M. Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects. J Infect Dis. 2014;210:890\u20138.","journal-title":"J Infect Dis"},{"key":"1367_CR11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/cei.12837","volume":"186","author":"JM Eberhard","year":"2016","unstructured":"Eberhard JM, Ahmad F, Hong HS, Bhatnagar N, Keudel P, Schulze Zur Wiesch J, Schmidt RE, Meyer-Olson D. Partial recovery of senescence and differentiation disturbances in CD8+ T cell effector-memory cells in HIV-1 infection after initiation of anti-retroviral treatment. Clin Exp Immunol. 2016;186:227\u201338.","journal-title":"Clin Exp Immunol"},{"key":"1367_CR12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/QAI.0b013e3181926c28","volume":"50","author":"W Cao","year":"2009","unstructured":"Cao W, Jamieson BD, Hultin LE, Hultin PM, Effros RB, Detels R. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr. 2009;50:137\u201347.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1367_CR13","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1073\/pnas.161126098","volume":"98","author":"JT Tan","year":"2001","unstructured":"Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, Weinberg KI, Surh CD. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci USA. 2001;98:8732\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1367_CR14","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1097\/01.aids.0000191919.24185.46","volume":"19","author":"F Boutboul","year":"2005","unstructured":"Boutboul F, Puthier D, Appay V, Pell\u00e9 O, Ait-Mohand H, Combadi\u00e8re B, Carcelain G, Katlama C, Rowland-Jones SL, Debr\u00e9 P, Nguyen C, Autran B. Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV. AIDS. 2005;19:1981\u20136.","journal-title":"AIDS"},{"key":"1367_CR15","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/eji.1830241202","volume":"24","author":"C Carini","year":"1994","unstructured":"Carini C, McLane MF, Mayer KH, Essex M. Dysregulation of interleukin-7 receptor may generate loss of cytotoxic T cell response in human immunodeficiency virus type 1 infection. Eur J Immunol. 1994;24:2927\u201334.","journal-title":"Eur J Immunol"},{"key":"1367_CR16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/QAI.0000000000000913","volume":"71","author":"CL Shive","year":"2016","unstructured":"Shive CL, Clagett B, McCausland MR, Mudd JC, Funderburg NT, Freeman ML, Younes SA, Ferrari BM, Rodriguez B, McComsey GA, Calabrese LH, Sieg SF, Lederman MM. Inflammation perturbs the IL-7 axis, promoting senescence and exhaustion that broadly characterize immune failure in treated HIV infection. J Acquir Immune Defic Syndr. 2016;71:483\u201392.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1367_CR17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/vim.2016.0046","volume":"29","author":"I Pulido","year":"2016","unstructured":"Pulido I, Genebat M, Alvarez-Rios AI, De Pablo-Bernal RS, Rafii-El-Idrissi Benhnia M, Pacheco YM, Ruiz-Mateos E, Leal M. Immunovirological efficacy of once-daily maraviroc plus ritonavir-boosted atazanavir after 48 weeks in naive HIV-infected patients. Viral Immunol. 2016;29:471\u20137.","journal-title":"Viral Immunol"},{"key":"1367_CR18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.imlet.2009.10.001","volume":"127","author":"S Ferrando-Martinez","year":"2010","unstructured":"Ferrando-Martinez S, Ruiz-Mateos E, Leal M. CD27 and CCR7 expression on naive T cells, are both necessary? Immunol Lett. 2010;127:157\u20138.","journal-title":"Immunol Lett"},{"key":"1367_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-4690-6-27","volume":"6","author":"I Garc\u00eda-Merino","year":"2009","unstructured":"Garc\u00eda-Merino I, de Las Cuevas N, Jim\u00e9nez JL, Gallego J, G\u00f3mez C, Prieto C, Serram\u00eda MJ, Lorente R, Mu\u00f1oz-Fern\u00e1ndez MA, Spanish HIVBioBank. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology. 2009;6:27.","journal-title":"Retrovirology"},{"key":"1367_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2014.03.048","volume":"184","author":"AJ Peris\u00e9-Barrios","year":"2014","unstructured":"Peris\u00e9-Barrios AJ, Jim\u00e9nez JL, Dom\u00ednguez-Soto A, de la Mata FJ, Corb\u00ed AL, Gomez R, Mu\u00f1oz-Fernandez M\u00c1. Carbosilane dendrimers as gene delivery agents for the treatment of HIV infection. J Control Release. 2014;184:51\u20137.","journal-title":"J Control Release"},{"key":"1367_CR21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3851\/IMP1861","volume":"16","author":"E Eynde Van den","year":"2011","unstructured":"Van den Eynde E, Quer J, Cubero M, Curran A, Homs M, Garcia-Cehic D, Falco V, Ribera E, Esteban JI, Pahissa A, Crespo M. Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system. Antivir Ther. 2011;16:887\u201393.","journal-title":"Antivir Ther"},{"key":"1367_CR22","first-page":"131","volume":"10","author":"E Lefebvre","year":"2008","unstructured":"Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 2008;10:131\u201342.","journal-title":"AIDS Rev"},{"key":"1367_CR23","doi-asserted-by":"crossref","first-page":"41018","DOI":"10.1038\/srep41018","volume":"7","author":"G Musumeci","year":"2017","unstructured":"Musumeci G, Bon I, Lembo D, Cagno V, Re MC, Signoretto C, Diani E, Lopalco L, Pastori C, Martin L, Ponchel G, Gibellini D, Bouchemal K. M48U1 and tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep. 2017;7:41018.","journal-title":"Sci Rep"},{"key":"1367_CR24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/135965350601100302","volume":"11","author":"K Borroto-Esoda","year":"2006","unstructured":"Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther. 2006;11:377\u201384.","journal-title":"Antivir Ther"},{"key":"1367_CR25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jiw077","volume":"214","author":"ML Cottrell","year":"2016","unstructured":"Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Hudgens MG, Wulff J, Patterson KB, Nelson JA, Kashuba AD. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214:55\u201364.","journal-title":"J Infect Dis"},{"key":"1367_CR26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.antiviral.2015.09.014","volume":"123","author":"M Mart\u00ednez-Bonet","year":"2015","unstructured":"Mart\u00ednez-Bonet M, Clemente MI, \u00c1lvarez S, D\u00edaz L, Garc\u00eda-Alonso D, Mu\u00f1oz E, Moreno S, Mu\u00f1oz-Fern\u00e1ndez M\u00c1. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal. Antivir Res. 2015;123:163\u201371.","journal-title":"Antivir Res"},{"key":"1367_CR27","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/eji.200839059","volume":"39","author":"SY Zhang","year":"2009","unstructured":"Zhang SY, Zhang Z, Fu JL, Kang FB, Xu XS, Nie WM, Zhou CB, Zhao M, Wang FS. Progressive CD127 down-regulation correlates with increased apoptosis of CD8 T cells during chronic HIV-1 infection. Eur J Immunol. 2009;39:1425\u201334.","journal-title":"Eur J Immunol"},{"key":"1367_CR28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.smim.2012.02.006","volume":"24","author":"AM Crawley","year":"2012","unstructured":"Crawley AM, Angel JB. The influence of HIV on CD127 expression and its potential implications for IL-7 therapy. Semin Immunol. 2012;24:231\u201340.","journal-title":"Semin Immunol"},{"key":"1367_CR29","doi-asserted-by":"crossref","first-page":"e47505","DOI":"10.1371\/journal.pone.0047505","volume":"7","author":"KR Hukezalie","year":"2012","unstructured":"Hukezalie KR, Thumati NR, C\u00f4t\u00e9 HC, Wong JM. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. PLoS ONE. 2012;7:e47505.","journal-title":"PLoS ONE"},{"key":"1367_CR30","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/QAD.0000000000001058","volume":"30","author":"HJ Stellbrink","year":"2016","unstructured":"Stellbrink HJ, Le Fevre E, Carr A, Saag MS, Mukwaya G, Nozza S, Valluri SR, Vourvahis M, Rinehart AR, McFadyen L, Fichtenbaum C, Clark A, Craig C, Fang AF, Heera J. Once-daily maraviroc versus tenofovir\/emtricitabine each combined with darunavir\/ritonavir for initial HIV-1 treatment. AIDS. 2016;30:1229\u201338.","journal-title":"AIDS"},{"key":"1367_CR31","doi-asserted-by":"crossref","first-page":"e1005540","DOI":"10.1371\/journal.ppat.1005540","volume":"12","author":"S Serrano-Villar","year":"2016","unstructured":"Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM. Effects of combined CCR5\/integrase inhibitors-based regimen on mucosal immunity in HIV-infected patients na\u00efve to antiretroviral therapy: a pilot randomized trial. PLoS Pathog. 2016;12:e1005540.","journal-title":"PLoS Pathog"},{"key":"1367_CR32","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/cid\/civ455","volume":"61","author":"BO Taiwo","year":"2015","unstructured":"Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T, AIDS Clinical Trials Group A5303 Study Team. Less bone loss with maraviroc- versus tenofovir-containing antiretroviral therapy in the AIDS clinical trials group A5303 study. Clin Infect Dis. 2015;61:1179\u201388.","journal-title":"Clin Infect Dis"},{"key":"1367_CR33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/QAI.0b013e31827b51b5","volume":"62","author":"A Mills","year":"2013","unstructured":"Mills A, Mildvan D, Podzamczer D, F\u00e4tkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. J Acquir Immune Defic Syndr. 2013;62:164\u201370.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1367_CR34","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1742-1241.2008.01817.x","volume":"62","author":"A Pozniak","year":"2008","unstructured":"Pozniak A. Tenofovir: what have over 1 million years of patient experience taught us? Int J Clin Pract. 2008;62:1285\u201393.","journal-title":"Int J Clin Pract"},{"key":"1367_CR35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/01.NPR.0000508167.22111.34","volume":"41","author":"L Meadowcraft","year":"2016","unstructured":"Meadowcraft L, Mospan G, Morrisette T, Smart K, Janis M. Drug updates and approvals: 2016 in review. Nurse Pract. 2016;41:20\u20137.","journal-title":"Nurse Pract"},{"key":"1367_CR36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","volume":"72","author":"D Wohl","year":"2016","unstructured":"Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M, GS-US-2,92-01040111 and Study Team. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72:58\u201364.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"71","key":"1367_CR37","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","volume":"2016","author":"A Pozniak","year":"2016","unstructured":"Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW, GS-US-292-0112 Study Team. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr. 2016;2016(71):530\u20137.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-017-1367-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T22:31:25Z","timestamp":1660170685000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-017-1367-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1367"],"URL":"https:\/\/doi.org\/10.1186\/s12967-017-1367-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"259"}}